FinscoFinsco

IDEAYA Biosciences (US.IDYA)

Capital Allocation Audit · Period: 2017 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.IDYA · YoY: 2026 Q1 vs 2025 Q1

MetricValueYoY
FCF Conversion101.3%→
ROE-10.5%↓
Cash Conversion-→
D/E Ratio0.03↓
Gross Margin0.0%→
US.IDYA (IDEAYA Biosciences) | YoY: 2026 Q1 vs 2025 Q1


Metric            Value  YoY
----------------------------
FCF Conversion   101.3%    →
ROE              -10.5%    ↓
Cash Conversion       -    →
D/E Ratio          0.03    ↓
Gross Margin       0.0%    →
Key Metrics
US.IDYA (IDEAYA Biosciences) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY
----------------------------
FCF Conversion 101.3% →
ROE -10.5% ↓
Cash Conversion - →
D/E Ratio 0.03 ↓
Gross Margin 0.0% →

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies